Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.

Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the ...

The facility will be built in the Netherlands and will increase capacity for the company's oral medicines portfolio ...

The Indianapolis-based pharmaceutical company said the new site will manufacture its weight-loss pill, orforglipron, and ...

American pharmaceutical giant Eli Lilly is investing 3 billion dollars (roughly 2.6 billion euros) to build a new factory in ...

The facility is expected to produce oral medications, including Lilly's highly anticipated GLP-1 pill for weight loss, orforglipron.

Eli Lilly is investing €2.6billion in a new Dutch factory, bringing around 500 jobs and a major boost to the Dutch biotech scene.

The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

Along with the company’s investment plans in Puerto Rico, Lilly also announced plans to build a $5 billon manufacturing plant ...